Is Biocon on the track to recovery?
A leading biopharmaceutical powerhouse, renowned for pioneering innovative drug development and biologics, is showing promising signs of market recovery. Recent financial moves include a strategic equity acquisition in its biologics division and an impressive 200% quarter-over-quarter profit growth, sparking investor interest as reflected in the company’s robust share price performance and market valuation.
Share Price Movement
The share price of Biocon Limited went up 3.89 percent to Rs. 370.90 per share on Friday, an increase from its previous close of Rs. 375 per share. The market capitalisation now stands at approximately Rs. 43,893 crore as of January 31, 2025.
What Happened
The board approved purchasing 1.5% equity in Biocon Biologics for Rs 555 crore, raising Biocon’s stake in Biocon Biologics to 90.2%.
Q3 – Financial Highlights
In Q3FY25, the company reported a revenue of Rs. 3,821 crore, a slight decrease from Rs. 3,954 crore in Q3FY24, showing a YoY decline of 3.37%. However, it grew 6.44% QoQ from Rs. 3,590 crore in Q2FY25. Profit for Q3FY25 stood at Rs. 81 crore, significantly lower compared to Rs. 753 crore in Q3FY24, a YoY decline of 89.22%, and a slight increase from Rs. 27 crore in Q2FY25, with a QoQ growth of 200%. Other income fell 93.8% to Rs 34.8 crore from Rs 565.5 crore.
Also read….
Competitors
Top competitors of BIOCON include Sun Pharmaceutical Industries Ltd, Divis Laboratories Ltd, Cipla Ltd, Torrent Pharmaceuticals Ltd, Panacea Biotec Ltd, Sai Life Sciences Ltd, and Vivo Bio Tech.
Biocon has a P/E of 22.39, which is lower than the industry P/E of 30.65.
Market Outlook
India’s pharmaceutical industry is growing rapidly, driven by cost efficiency, strong manufacturing, and government support. With low-cost production and skilled labor, India remains the “Pharmacy of the World.” The sector is expected to reach $130 billion by 2030. Government initiatives like the PLI scheme and SPI support further boost investment and innovation. India’s dominance in affordable medicines, vaccines, and medical tourism strengthens its global presence. Revenue growth of 9-11% in FY25 highlights a promising future for the industry.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
Start Your Stock Market Journey Today!
Want to learn Stock Market trading and Investing? Make sure to check out exclusive Stock Market courses by FinGrad, the learning initiative by Trade Brains. You can enroll in FREE courses and webinars available on FinGrad today and get ahead in your trading career. Join now!!
